Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study

Once‐weekly alendronate 70 mg and once‐weekly risedronate 35 mg are indicated for the treatment of postmenopausal osteoporosis. These two agents were compared in a 12‐month head‐to‐head trial. Greater gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability.

[1]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  Ego Seeman,et al.  Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. , 2004, Bone.

[3]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[4]  J. Reginster,et al.  Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  C. Cooper,et al.  Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta‐Analyses , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  P. Delmas,et al.  Long‐Term Variability of Markers of Bone Turnover in Postmenopausal Women and Implications for Their Clinical Use: The OFELY Study , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  J. Reginster,et al.  Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. , 2003, Maturitas.

[9]  R. Eastell,et al.  Biochemical Markers of Bone Turnover and Fracture Prediction , 2003, The journal of the British Menopause Society.

[10]  J. Reginster,et al.  Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study , 2003, Current medical research and opinion.

[11]  Jacques P. Brown,et al.  The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis , 2002, Calcified Tissue International.

[12]  Gordon Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.

[13]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. , 2002, Endocrine reviews.

[14]  G. Guyatt,et al.  III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis , 2002 .

[15]  M. Hochberg,et al.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  Fran Harris,et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.

[17]  R. Marcus,et al.  Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. , 2002, Endocrine reviews.

[18]  D. Black,et al.  Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Ellen Fineout-Overholt,et al.  Users' Guides to the Medical Literature , 2002 .

[20]  C. Chesnut,et al.  Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Meredith,et al.  A method to assess the proportion of treatment effect explained by a surrogate endpoint , 2001, Statistics in medicine.

[22]  E. Siris,et al.  Importance of precision in bone density measurements. , 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[23]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  D. Burr,et al.  Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis , 2000, Aging.

[26]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .

[27]  D L Sackett,et al.  Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. , 1999, JAMA.

[28]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[29]  G. Guyatt,et al.  Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. , 1999, JAMA.

[30]  S. Cummings,et al.  Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. , 1999, Arthritis and rheumatism.

[31]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[32]  Ron Johnston,et al.  Review of A Solution to the Ecological Inference Problem: Reconstructing Individual Behaviour from Aggregate Data by King, G , 1998 .

[33]  M F Huque,et al.  Some comments on frequently used multiple endpoint adjustment methods in clinical trials. , 1997, Statistics in medicine.

[34]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  S. Cummings,et al.  Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. , 1995, Arthritis and rheumatism.

[37]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[38]  H K Genant,et al.  Axial and appendicular bone density predict fractures in older women , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  M. Peacock,et al.  Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women , 2007, Osteoporosis International.

[40]  O. Johnell,et al.  Uncertain Future of Trials in Osteoporosis , 2002, Osteoporosis International.

[41]  G. Guyatt,et al.  Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .

[42]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. , 2002, Endocrine reviews.

[43]  C. Christiansen,et al.  Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.

[44]  P. Miller,et al.  Antifracture efficacy of antiresorptive agents are related to changes in bone density. , 2000, The Journal of clinical endocrinology and metabolism.

[45]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[46]  D. Hans,et al.  Do Markers of Bone Resorption Add to Bone Mineral Density and Ultrasonographic Heel Measurement for the Prediction of Hip Fracture in Elderly Women? The EPIDOS Prospective Study , 1998, Osteoporosis International.

[47]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.